Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eiger Has Positive Data For Its COVID-19 Drug, But Faces Uncertain Market

Executive Summary

Peginterferon lambda helped reduce hospitalizations and deaths among high-risk COVID-19 patients in a Phase III trial.

You may also be interested in...



Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid

The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.

Gilead Sees HIV Business Return To Sales Growth As Oncology Gets Boost

The company said screening and diagnosis were still below pre-pandemic levels, but Biktarvy and Descovy brought HIV sales back into positive territory.

Moderna Sees Key Role For Respiratory Vaccines As COVID-19 Goes Endemic

The company anticipates another year of big sales for its COVID-19 vaccine, but is also touting a pipeline of 44 programs in development, with oncology and possibly rare disease data this year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146077

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel